CYBN
ACHAT TOTAL: 90000 titres (~1042677 USD)
- Insiders
- Glavine Paul
- Total bought
- $1,042,677
- Total sold
- —
- Last activity
- 2026-08-31
- Last synced
-
2026-09-10 10:26:50
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-09-10
CYBN presents a mixed profile: a meaningful insider cluster buy (~$1.04M) with solid catalyst confidence (0.7) signals genuine insider conviction, supported by positive sector tailwinds from J&J's Spravato growth.
The first sentence of the analysis written for CYBN on 2026-09-10 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 23.1% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | -3728.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | -3722.3% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | -3592.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | -3729.2% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | -3729.2% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | -3729.2% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | -3729.2% | |
| Current Ratio | 7.749 | 21.646 | 2.932 | 11.909 | 13.568 | |
| Quick Ratio | 7.749 | 21.646 | 2.771 | 11.952 | 13.568 | |
| Solvency Ratio | -5.260 | -7.708 | -5.033 | -11.888 | -5.367 | |
| Cash Ratio | 6.304 | 20.700 | 2.103 | 10.947 | 13.067 | |
| Price To Earnings Ratio | -14.952 | -5.575 | -89.877 | -90.284 | -0.000 | |
| Price To Earnings Growth Ratio | 0.177 | -0.003 | 1.840 | 0.903 | -0.000 | |
| Forward Price To Earnings Growth Ratio | 0.177 | -0.003 | 1.840 | 0.903 | -0.000 | |
| Price To Earnings Diluted Ratio | -14.952 | -2.316 | -89.877 | -90.284 | -0.000 | |
| Price To Earnings Diluted Growth Ratio | 0.160 | -0.001 | 1.840 | 0.903 | -0.000 | |
| Price To Book Ratio | 7.130 | 13.845 | 76.015 | 85.279 | 0.000 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.001 | |
| Price To Free Cash Flow Ratio | -16.378 | -58.057 | -80.182 | -337.233 | -0.000 | |
| Price To Operating Cash Flow Ratio | -16.696 | -58.656 | -81.105 | -341.327 | -0.000 | |
| Debt To Assets Ratio | 0.000 | 0.001 | 0.000 | 0.000 | 0.000 | |
| Debt To Equity Ratio | 0.000 | 0.001 | 0.000 | 0.000 | 0.000 | |
| Debt To Capital Ratio | 0.000 | 0.001 | 0.000 | 0.000 | 0.000 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.090 | 1.035 | 1.117 | 1.104 | 1.070 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.027 | |
| Operating Cash Flow Ratio | -4.730 | -6.825 | -5.717 | -3.883 | -3.883 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | -22.022 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.019 | 1.010 | 1.012 | 1.012 | 1.012 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | -3,216.100 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | -3,103.500 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.000 | -236.797 | 0.000 | 0.000 | 0.000 | |
| Capital Expenditure Coverage Ratio | -51.526 | -97.054 | -86.937 | -82.368 | -82.368 | |
| Dividend Paid And Capex Coverage Ratio | -51.526 | -97.054 | -86.937 | -82.368 | -82.368 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -10.908 | -48.783 | -71.168 | -101.159 | 1.991 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | ▼-4.6% |
| Ebit Margin | 0.0% | 0.0% | ▲745.6% |
| Ebitda Margin | 0.0% | 0.0% | ▲744.5% |
| Operating Profit Margin | 0.0% | 0.0% | ▲718.4% |
| Pretax Profit Margin | 0.0% | 0.0% | ▲745.8% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | ▲745.8% |
| Net Profit Margin | 0.0% | 0.0% | ▲745.8% |
| Bottom Line Profit Margin | 0.0% | 0.0% | ▲745.8% |
| Current Ratio | 7.749 | ▼-13.897 | ▼-3.812 |
| Quick Ratio | 7.749 | ▼-13.897 | ▼-3.788 |
| Solvency Ratio | -5.260 | ▲2.448 | ▲1.791 |
| Cash Ratio | 6.304 | ▼-14.396 | ▼-4.320 |
| Price To Earnings Ratio | -14.952 | ▼-9.377 | ▲25.186 |
| Price To Earnings Growth Ratio | 0.177 | ▲0.180 | ▼-0.406 |
| Forward Price To Earnings Growth Ratio | 0.177 | ▲0.180 | ▼-0.406 |
| Price To Earnings Diluted Ratio | -14.952 | ▼-12.636 | ▲24.534 |
| Price To Earnings Diluted Growth Ratio | 0.160 | ▲0.160 | ▼-0.421 |
| Price To Book Ratio | 7.130 | ▼-6.715 | ▼-29.324 |
| Price To Sales Ratio | 0.000 | 0.000 | ▼-0.000 |
| Price To Free Cash Flow Ratio | -16.378 | ▲41.680 | ▲81.993 |
| Price To Operating Cash Flow Ratio | -16.695 | ▲41.960 | ▲82.861 |
| Debt To Assets Ratio | 0.000 | ▼-0.001 | ▼-0.000 |
| Debt To Equity Ratio | 0.000 | ▼-0.001 | ▼-0.000 |
| Debt To Capital Ratio | 0.000 | ▼-0.001 | ▼-0.000 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.090 | ▲0.056 | ▲0.007 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | ▼-0.005 |
| Operating Cash Flow Ratio | -4.730 | ▲2.096 | ▲0.278 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | ▲4.404 |
| Free Cash Flow Operating Cash Flow Ratio | 1.019 | ▲0.009 | ▲0.006 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | ▲643.220 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▲620.700 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | 0.000 | ▲236.797 | ▲47.359 |
| Capital Expenditure Coverage Ratio | -51.526 | ▲45.528 | ▲28.524 |
| Dividend Paid And Capex Coverage Ratio | -51.526 | ▲45.528 | ▲28.524 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -10.908 | ▲37.875 | ▲35.098 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.69B | $4.04B | $3.67B | $6.49B | $498 | |
| Enterprise value | $1.56B | $3.83B | $3.65B | $6.44B | -$64.0M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | -74.10x | |
| EV / Op. cash flow | -15.36x | -55.63x | -80.74x | -338.51x | 3.37x | |
| EV / Free cash flow | -15.07x | -55.06x | -79.82x | -334.45x | 3.33x | |
| EV / EBITDA | -10.91x | -48.78x | -71.17x | -101.16x | 1.99x | |
| Net debt / EBITDA | 0.95x | 2.66x | 0.32x | 0.84x | 1.99x | |
| Current ratio | 7.75x | 21.65x | 2.93x | 11.91x | 13.57x | |
| Income quality | 0.90x | 0.88x | 0.95x | 0.28x | 0.59x | |
| Graham net-net | $1 | $1 | $0 | $0 | $5.9M | |
| Tax burden | 100.0% | 100.0% | 84.3% | 105.6% | 100.0% | |
| Interest burden | 79.0% | 99.0% | 92.2% | 105.9% | 100.0% | |
| Working capital | $144.6M | $208.4M | $15.3M | $53.5M | $61.6M | |
| Invested capital | $237.2M | $291.9M | $40.7M | $79.1M | $87.2M | |
| Return on assets | -43.7% | -25.9% | -74.3% | -85.0% | -35.0% | |
| Operating ROA | -51.1% | -44.3% | -74.7% | -72.5% | -66.2% | |
| Return on tangible assets | -68.1% | -35.6% | -138.4% | -121.1% | -48.1% | |
| Return on equity | -47.7% | -26.7% | -83.0% | -93.8% | -37.4% | |
| Return on invested capital | -60.3% | -27.0% | -112.0% | -80.7% | -35.6% | |
| Return on capital employed | -60.3% | -27.0% | -112.0% | -80.6% | -35.6% | |
| Earnings yield | -6.7% | -1.9% | -1.1% | -1.1% | -6469923.7% | |
| Free cash flow yield | -6.1% | -1.7% | -1.2% | -0.3% | -3867094.7% | |
| Capex / Op. cash flow | -1.9% | -1.0% | -1.2% | -1.2% | -1.2% | |
| Capex / Depreciation | 413.9% | 167.5% | 207.2% | 137.5% | 471.4% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 26.7% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 3174.1% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 381.9% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 1337.3% | |
| Intangibles / Total assets | 35.8% | 27.5% | 46.3% | 29.8% | 27.2% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 561d | |
| Days payables outstanding | 23686d | 8441d | 8235d | 11432d | 1535d | |
| Operating cycle | 0d | 0d | 1848d | -461d | 561d | |
| Cash conversion cycle | -23686d | -8441d | -6387d | -11893d | -974d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-58.2%EV / Sales n/aEV / EBITDA ▲+77.6%EV / Op. cash flow ▲+40.264Earnings yield ▼-0.048
Profitability
Return on equity ▼-0.210Return on assets ▼-0.179Return on invested capital ▼-0.334Return on capital employed ▼-0.333Operating ROA ▼-0.068Income quality ▲+0.013Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding ▲+15245.464Operating cycle n/aCash conversion cycle ▼-15245.464Capex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-13.897Net debt / EBITDA ▼-1.710Working capital ▼-63886000.000Invested capital ▼-54727000.000Intangibles / Total assets ▲+0.083
Change over 5 years
Valuation
Market cap ▲+339611931.4%EV / Sales ▲+100.0%EV / EBITDA ▼-647.9%EV / Op. cash flow ▼-18.728Earnings yield ▲+64699.170
Profitability
Return on equity ▼-0.103Return on assets ▼-0.088Return on invested capital ▼-0.248Return on capital employed ▼-0.248Operating ROA ▲+0.151Income quality ▲+0.305Tax burden 0.000
Efficiency
Days sales outstanding ▼-561.441Days payables outstanding ▲+22150.780Operating cycle ▼-561.441Cash conversion cycle ▼-22712.221Capex / Sales ▼-0.267R&D / Sales ▼-3.819
Balance-sheet strength
Current ratio ▼-5.819Net debt / EBITDA ▼-1.044Working capital ▲+82970000.000Invested capital ▲+149988000.000Intangibles / Total assets ▲+0.086
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-07-15 Johnson & Johnson’s Spravato sales growth supports psychedelic drug opportunity: Jefferies Psychedelic drug developers including AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC), Compass Pathways (NASDAQ:CMPS) and Cybin Inc. (NYSE-A:CYBN, FRA:R7E) could...
- 2026-07-14 CleanSpark shares surge after company secures $6.6B data center lease agreement CleanSpark Inc (NASDAQ:CLSK) shares surged more than 12% after the company announced a 20-year lease agreement for its Sandersville, Georgia data center...
- 2026-07-14 Tower Semiconductor shares jump as company announces Japan expansion to boost silicon photonics capacity Tower Semiconductor (NASDAQ:TSEM) shares rose 13% on Tuesday after the company announced a strategic expansion of its silicon photonics, silicon germanium...
- 2026-06-27 Cybin: A Speculative Bet On Their Pivotal Depression Readout Cybin operates as Helus Pharma, which is a clinical-stage biotech built around deuterated serotonergic therapies for depression and anxiety. I believe their main value driver is HLP003, which will report in Q4 2026 its Phase 3 APPROACH readout. HELP also recently raised funds in June 2026, and they don''t have financial debt. So, they should have enough resources to reach this important milestone later this year.